A microarray patch SARS-CoV-2 vaccine induces sustained antibody responses and polyfunctional cellular immunity.

Autor:	Balmert SC; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA., Ghozloujeh ZG; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA., Carey CD; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA., Williams LH; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA., Zhang J; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA., Shahi P; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA., Amer M; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA., Sumpter TL; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA., Erdos G; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA., Korkmaz E; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.; Department of Bioengineering, University of Pittsburgh Swanson School of Engineering, Pittsburgh, PA 15261, USA., Falo LD Jr; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.; Department of Bioengineering, University of Pittsburgh Swanson School of Engineering, Pittsburgh, PA 15261, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.; The McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15219, USA.
Jazyk:	angličtina
Zdroj:	IScience [iScience] 2022 Oct 21; Vol. 25 (10), pp. 105045. Date of Electronic Publication: 2022 Aug 30.
DOI:	10.1016/j.isci.2022.105045
Abstrakt:	Sustainable global immunization campaigns against COVID-19 and other emerging infectious diseases require effective, broadly deployable vaccines. Here, we report a dissolvable microarray patch (MAP) SARS-CoV-2 vaccine that targets the immunoresponsive skin microenvironment, enabling efficacious needle-free immunization. Multicomponent MAPs delivering both SARS-CoV-2 S1 subunit antigen and the TLR3 agonist Poly(I:C) induce robust antibody and cellular immune responses systemically and in the respiratory mucosa. MAP vaccine-induced antibodies bind S1 and the SARS-CoV-2 receptor-binding domain, efficiently neutralize the virus, and persist at high levels for more than a year. The MAP platform reduces systemic toxicity of the delivered adjuvant and maintains vaccine stability without refrigeration. When applied to human skin, MAP vaccines activate skin-derived migratory antigen-presenting cells, supporting the feasibility of human translation. Ultimately, this shelf-stable MAP vaccine improves immunogenicity and safety compared to traditional intramuscular vaccines and offers an attractive alternative for global immunization efforts against a range of infectious pathogens. Competing Interests: E. Korkmaz and L.D. Falo Jr. are inventors of related intellectual property. L.D. Falo Jr. is a co-founder and scientific advisor of SkinJect, a company that is developing dissolvable MAPs for treatment of non-melanoma skin cancer. (© 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu